Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-16-Speech-3-213-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110216.11.3-213-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"We voted for the Matias report on falsified medicines. This is indeed a public health and safety issue in a Europe without borders where the worst counterfeit or simply poor-quality rubbish can circulate freely. However, there is no guarantee that, in matters of health, medicine or pharmacovigilance, the European Union is best placed to resolve any problems that may arise. It may even be the cause of them, for example with the 2004 Directive on traditional herbal medicinal products, coupled with the 2006 Regulation on health claims. The former includes the requirement for products to be registered with the European Medicines Agency, a procedure so complex and so costly that only 200 herbal medicinal products had been registered by the end of 2010. The other gives the European Food Safety Authority the power to authorise or not health claims for food supplements, including plants, an authorisation which it gives so rarely and refuses on such arbitrary grounds that it has even upset the Commission. The upshot is that European legislation will end up favouring chemical medicines and pharmaceutical laboratories. Is there a desire to eradicate the natural medicines sector? Who or what will benefit from this? Not necessarily the health of the people of Europe."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples